BRAF and neoplasm: Of note, a paradoxical activation of ERK signaling after targeting with B‐RAFV600E inhibitors (vemurafenib and dabrafenib) was documented by others for RAS‐mutated and B‐RAF wild‐type tumor cells (Hatzivassiliou et al, 2010; Poulikakos et al, 2010).